Dickkopf-1:缺血性卒中的潜在治疗靶点  

Dickkopf-1:a potential therapeutic target for ischemic stroke

作　　者：柴国蓉 陈美艳 徐恩[1] Chai Guorong;Chen Meiyan;Xu En(Institute of Neurosciences,Department of Neurology,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China)

机构地区：[1]广州医科大学神经科学研究所,广州医科大学附属第二医院神经内科,广州510260

出　　处：《国际脑血管病杂志》2023年第9期698-702,共5页International Journal of Cerebrovascular Diseases

基　　金：国家自然科学基金(82071281);广东省自然科学基金(2021A1515011269)。

摘　　要：Dickkopf-1(DKK1)是一种分泌型糖蛋白,作为Wnt/β-连环素通路的抑制剂,在胚胎发育、神经发生和突触发生等方面发挥重要作用。脑缺血后,DKK1通过促进神经元凋亡及血脑屏障损伤,抑制神经发生和血管生成,从而加重脑损伤。此外,缺血性卒中患者血清DKK1与不同病期及转归相关。因此,开发以DKK1作为靶点的特异抑制剂,有望应用于缺血性卒中的治疗。Dickkopf-1(DKK1)is a secreted glycoprotein that acts as an inhibitor of the Wnt/β-catenin pathway and plays an important role in embryonic development,neurogenesis and synaptogenesis.After cerebral ischemia,DKK1 inhibits neurogenesis and angiogenesis by promoting neuronal apoptosis and blood-brain barrier damage,thus aggravating brain injury.In addition,serum DKK1 in patients with ischemic stroke was associated with different disease stages and outcomes.Therefore,the development of specific inhibitors targeting DKK1 is expected to be applied in the treatment of ischemic stroke.

关 键 词：卒中 脑缺血 Β-连环素 WNT信号通路 细胞凋亡 神经发生 生物标志物 DICKKOPF-1 

分 类 号：R743.3[医药卫生—神经病学与精神病学]